CD73 inhibition may be a promising therapeutic strategy to reduce carotid body hyperactivity and decrease ABP in CH‐related diseases like COPD, without compromising the critical ability to respond to severe hypoxia. Here, NT5E is linked to cyclic hematopoiesis.